Amgen and Astellas Pharma have entered into a strategic alliance to provide new medicines to help address serious unmet medical needs of Japanese patients. The alliance combines Amgen’s pipeline with Astellas’ experience in Japan. The first element of the alliance is a long-term collaboration that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline drugs. The five candidates include four biologics and one small molecule and are focused on the tr...